Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Melanoma Skin Cancer Diagnostic Testing
1.2 Key Market Segments
1.2.1 Melanoma Skin Cancer Diagnostic Testing Segment by Type
1.2.2 Melanoma Skin Cancer Diagnostic Testing Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Melanoma Skin Cancer Diagnostic Testing Market Overview
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Melanoma Skin Cancer Diagnostic Testing Market Competitive Landscape
3.1 Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Company (2019-2024)
3.2 Melanoma Skin Cancer Diagnostic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Melanoma Skin Cancer Diagnostic Testing Market Size Sites, Area Served, Product Type
3.4 Melanoma Skin Cancer Diagnostic Testing Market Competitive Situation and Trends
3.4.1 Melanoma Skin Cancer Diagnostic Testing Market Concentration Rate
3.4.2 Global 5 and 10 Largest Melanoma Skin Cancer Diagnostic Testing Players Market Share by Revenue
3.4.3 Mergers & Acquisitions, Expansion
4 Melanoma Skin Cancer Diagnostic Testing Value Chain Analysis
4.1 Melanoma Skin Cancer Diagnostic Testing Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 The Development and Dynamics of Melanoma Skin Cancer Diagnostic Testing Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 Mergers & Acquisitions
5.5.2 Expansions
5.5.3 Collaboration/Supply Contracts
5.6 Industry Policies
6 Melanoma Skin Cancer Diagnostic Testing Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Melanoma Skin Cancer Diagnostic Testing Market Size Market Share by Type (2019-2024)
6.3 Global Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Type (2019-2024)
7 Melanoma Skin Cancer Diagnostic Testing Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Melanoma Skin Cancer Diagnostic Testing Market Size (M USD) by Application (2019-2024)
7.3 Global Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Application (2019-2024)
8 Melanoma Skin Cancer Diagnostic Testing Market Segmentation by Region
8.1 Global Melanoma Skin Cancer Diagnostic Testing Market Size by Region
8.1.1 Global Melanoma Skin Cancer Diagnostic Testing Market Size by Region
8.1.2 Global Melanoma Skin Cancer Diagnostic Testing Market Size Market Share by Region
8.2 North America
8.2.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Melanoma Skin Cancer Diagnostic Testing Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Myriad Genetics
9.1.1 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Basic Information
9.1.2 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Product Overview
9.1.3 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.1.4 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing SWOT Analysis
9.1.5 Myriad Genetics Business Overview
9.1.6 Myriad Genetics Recent Developments
9.2 Abbott Laboratories
9.2.1 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Basic Information
9.2.2 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Product Overview
9.2.3 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.2.4 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing SWOT Analysis
9.2.5 Abbott Laboratories Business Overview
9.2.6 Abbott Laboratories Recent Developments
9.3 Foundation Medicine
9.3.1 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Basic Information
9.3.2 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Product Overview
9.3.3 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.3.4 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing SWOT Analysis
9.3.5 Foundation Medicine Business Overview
9.3.6 Foundation Medicine Recent Developments
9.4 Pathway Genomics Corporation
9.4.1 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Basic Information
9.4.2 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Product Overview
9.4.3 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.4.4 Pathway Genomics Corporation Business Overview
9.4.5 Pathway Genomics Corporation Recent Developments
9.5 Cancer Genetics
9.5.1 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Basic Information
9.5.2 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Product Overview
9.5.3 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.5.4 Cancer Genetics Business Overview
9.5.5 Cancer Genetics Recent Developments
9.6 Castle Biosciences
9.6.1 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Basic Information
9.6.2 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Product Overview
9.6.3 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.6.4 Castle Biosciences Business Overview
9.6.5 Castle Biosciences Recent Developments
9.7 NeoGenomics
9.7.1 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Basic Information
9.7.2 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Product Overview
9.7.3 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.7.4 NeoGenomics Business Overview
9.7.5 NeoGenomics Recent Developments
9.8 Dermtech
9.8.1 Dermtech Melanoma Skin Cancer Diagnostic Testing Basic Information
9.8.2 Dermtech Melanoma Skin Cancer Diagnostic Testing Product Overview
9.8.3 Dermtech Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.8.4 Dermtech Business Overview
9.8.5 Dermtech Recent Developments
9.9 Sysmex Inostics
9.9.1 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Basic Information
9.9.2 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Product Overview
9.9.3 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Product Market Performance
9.9.4 Sysmex Inostics Business Overview
9.9.5 Sysmex Inostics Recent Developments
10 Melanoma Skin Cancer Diagnostic Testing Regional Market Forecast
10.1 Global Melanoma Skin Cancer Diagnostic Testing Market Size Forecast
10.2 Global Melanoma Skin Cancer Diagnostic Testing Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Country
10.2.3 Asia Pacific Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Region
10.2.4 South America Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Melanoma Skin Cancer Diagnostic Testing by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Melanoma Skin Cancer Diagnostic Testing Market Forecast by Type (2025-2030)
11.2 Global Melanoma Skin Cancer Diagnostic Testing Market Forecast by Application (2025-2030)
12 Conclusion and Key Findings
